Robert W. Baird Sticks to Its Hold Rating for Voyager Therapeutics (VYGR)

By Carrie Williams

Robert W. Baird analyst Brian Skorney maintained a Hold rating on Voyager Therapeutics (VYGRResearch Report) on May 10 and set a price target of $6.00. The company’s shares closed last Wednesday at $4.47, close to its 52-week low of $3.89.

According to, Skorney is a 3-star analyst with an average return of 4.3% and a 48.5% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Voyager Therapeutics with a $5.63 average price target, representing a 30.9% upside. In a report issued on April 26, Wedbush also maintained a Hold rating on the stock with a $6.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $14.62 and a one-year low of $3.89. Currently, Voyager Therapeutics has an average volume of 613.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.